The myelodysplastic syndrome (MDS) drugs market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.
The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved a generic injectable product, decitabine for Lupin Ltd. There are various other MDS medications available in the market.
Various other factors such as the promotion of clinical studies related to MS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drug manufacturers are boosting the market growth.
However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.
The myelodysplastic syndrome (MDS) drugs market is segmented based on type, type of syndrome, route of administration, end user, and region.
Based on type, the myelodysplastic syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.
Based on the type of syndrome, the MDS drugs market at the global level is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.
Based on the route of administration, the market is segmented into oral, parenteral, and others.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others.
The segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The myelodysplastic syndrome (MDS) drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Myelodysplastic Syndrome (MDS) drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Myelodysplastic Syndrome (MDS) drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The myelodysplastic syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Myelodysplastic syndrome (MDS) drugs market Share (%), by Region, 2018
Sources: MRFR Analysis
The Americas dominated the global MDS drugs market, owing to the increasing number of patients detected with MDS yearly. According to the statistics published by the American Society of Clinical Oncology in 2019, around 10,000 patients are detected with MDS in the US yearly.
In the European region, various studies have been performed to study the prevalence of MDS across different age groups. For instance, the National Institutes of Health conducted a successive study among children with MDS for 15 years. Under the study, 426 children were investigated for Germline GATA-2 mutations and primary MDS. The studies revealed that Germline GATA-2 mutations highly prevailed in patients with monosomy 7 type of mutation. Thus, the European region has a potential scope for the MDS drugs market.
Asia-Pacific is expected to grow owing to the rising research and development activities in this region. The study of clinical features is very important before proceeding for treatment methodology for a patient. As per the study published in the Leukemia Journal in 2018, the difference in clinical features among the Japanese and Caucasian patients with myelodysplastic syndromes was noticed. The study revealed that; chronic lymphocytic leukemia is more frequent in the Caucasians population than the Japanese population. This could be due to susceptibility specific location of the genome. Thus, the MDS drugs market in APAC is predicted to gain the third-largest market share.
The Middle East and Africa held the least share in the myelodysplastic syndrome (MDS) drugs market due to low economic development, especially within the African region.
Myelodysplastic syndrome (MDS) drugs market, by Type
Myelodysplastic syndrome (MDS) drugs market, by Type of Syndrome
Myelodysplastic syndrome (MDS) drugs market, by Route of Administration
Myelodysplastic syndrome (MDS) drugs market, by End User
|Market Size||2025: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug Type, Type of Syndrome, End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr. Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries Inc|
|Key Market Opportunities||The increasing participation of key players is one of the key factors|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Myelodysplastic Syndrome (MDS) drugs market would record a CAGR of 10.1% during the forecast period of 2019-2025.
Myelodysplastic Syndrome (MDS) drugs market had a valuation of USD 1581.59 million in 2018.
The risk of infection with blood transfusion and chemotherapy’s side-effects can hold back the growth of the Myelodysplastic Syndrome (MDS) drugs market.
Myelodysplastic Syndrome (MDS) drugs market report includes a discussion of oral, parenteral, and others.
The Americas would hold the Myelodysplastic Syndrome (MDS) drugs market lead.